Incorporated in 2002, Sequent Scientific Limited is engaged in the business of providing a wide-ranging portfolio of animal health products, including Finished Dose Formulations and APIs, as well as analytical services to the pharmaceutical and life sciences industries. In 2003, the Hon'ble Bombay High Court approved the Scheme of Amalgamation of the company with P I Drugs and Pharmaceuticals Ltd. The company’s name was changed from PI Drugs and Pharmaceuticals Ltd to Sequent Scientific Ltd._x000D_ _x000D_ In 2013, Sequent Scientific Ltd announced a joint venture with Shasun Pharmaceuticals Ltd to establish a leading animal health company. The company continued its operational growth and achieved numerous milestones in 2014. During the year, the company announced the completion of the sale of the speciality chemicals division to Songwon Industrial Group. In addition, it acquired the business of Arvee Synthesis to provide impetus to the Human API business. In 2016, the company acquired a controlling stake in Indo Phyto Chemicals and entered into steroids and hormones. During the same year, it commenced production in the Vizag facility. _x000D_ _x000D_ The company’s arm, Alivira, received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh in 2017. In 2020, the company announced the addition of a new state-of-the-art Animal Health R&D Centre in Mumbai. During the same year, it received EIR from the US FDA for its Analytical Laboratory in Bengaluru. In 2021, the company entered into the pet segment in Brazil. During the same year, the European Union Good Manufacturing Practices (EUGMP) received approval for its tablet dosage manufacturing line in Turkey._x000D_

Business Segments

_x000D_

_x000D_
• API: Under this segment, the company is engaged in the manufacturing of API.  API business has 29 USVMFs + 18 CEPs (registered 5 VMFs and 3 CEPs in FY23) as of FY 2023. The company signed a long-term master supply arrangement with a global Top-10 animal health company. API has 30+ commercial APIs with 3 manufacturing facilities and 1 R&D center. The company made new investments in capacity expansion for leading customers and in expanding its own R&D capacity. The company launched 4 new API products in FY 2023.
_x000D_
• Formulation: The company has over 1000  final dosage formulations, 5 R&D centres devoted to the formulation industry, 6 manufacturing facilities in Europe, Turkey, Brazil, and India, and a marketing presence in more than 100 countries. In an effort to increase profitability, the company closed its manufacturing operations in its Germany factory in FY23 and relocated to a less expensive location. In FY23, their new Phyto line was introduced. 
_x000D_

_x000D_ Subsidiaries_x000D_ _x000D_ As of FY23, the company has 21 Subsidiaries, out of which 14 are Wholly Owned, and a few of them are listed below:_x000D_

_x000D_
• Alivira Animal Health Limited: It is a wholly-owned subsidiary which was incorporated on September 30, 2013. It is the largest and 1st Global integrated animal health company specialising in the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
_x000D_
• Laboratorios Karizoo S.A: This wholly-owned subsidiary was incorporated on May 09, 1983. Since its inception, the company has served the veterinary pharmaceutical sector.
_x000D_

_x000D_

Key Personnel

_x000D_ Mr. Rajaram Narayanan, Managing Director_x000D_ _x000D_ Mr Narayanan has over 25 years of experience and possesses a strong track record of leading revenue and profitability growth throughout multiple industries, including pharmaceuticals. Prior to joining the company, he worked with Sanofi India Limited as the Managing Director and Country Chair for India. He led the strategic reorientation of Sanofi’s  India business operations. _x000D_ _x000D_ Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands. He is a BE (Hons)-Electrical and Electronics graduate from Birla Institute of Technology and Science, Pilani, and an MBA from the Indian Institute of Foreign Trade, New Delhi. He has completed the Advanced Management Program at Harvard Business School, USA._x000D_

Corporate Actions

_x000D_ The company has no history of bonus issues, stock splits and other corporate actions.